Correlation Between Morgan Stanley and Spyre Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and Spyre Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and Spyre Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Morgan Stanley and Spyre Therapeutics, you can compare the effects of market volatilities on Morgan Stanley and Spyre Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of Spyre Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and Spyre Therapeutics.

Diversification Opportunities for Morgan Stanley and Spyre Therapeutics

0.74
  Correlation Coefficient

Poor diversification

The 3 months correlation between Morgan and Spyre is 0.74. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley and Spyre Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spyre Therapeutics and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley are associated (or correlated) with Spyre Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spyre Therapeutics has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and Spyre Therapeutics go up and down completely randomly.

Pair Corralation between Morgan Stanley and Spyre Therapeutics

Allowing for the 90-day total investment horizon Morgan Stanley is expected to generate 0.74 times more return on investment than Spyre Therapeutics. However, Morgan Stanley is 1.35 times less risky than Spyre Therapeutics. It trades about -0.13 of its potential returns per unit of risk. Spyre Therapeutics is currently generating about -0.41 per unit of risk. If you would invest  11,169  in Morgan Stanley on January 7, 2025 and sell it today you would lose (1,077) from holding Morgan Stanley or give up 9.64% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Morgan Stanley  vs.  Spyre Therapeutics

 Performance 
       Timeline  
Morgan Stanley 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Morgan Stanley has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in May 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Spyre Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Spyre Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in May 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Morgan Stanley and Spyre Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Morgan Stanley and Spyre Therapeutics

The main advantage of trading using opposite Morgan Stanley and Spyre Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, Spyre Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will offset losses from the drop in Spyre Therapeutics' long position.
The idea behind Morgan Stanley and Spyre Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Complementary Tools

Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings